Kipp Weiskopf
Affiliations: | Whitehead Institute for Biomedical Research (MIT) |
Area:
Cancer ImmunotherapyGoogle:
"Kipp Weiskopf"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Allen J, Meglan A, Vaccaro K, et al. (2024) CD47 predominates over CD24 as a macrophage immune checkpoint in cancer. Biorxiv : the Preprint Server For Biology |
| Ribeiro J, Pagès-Geli C, Meglan A, et al. (2024) Unbiased discovery of antibody therapies that stimulate macrophage-mediated destruction of B-cell lymphoma. Biorxiv : the Preprint Server For Biology |
| Vaccaro K, Allen J, Whitfield TW, et al. (2024) Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. The Journal of Clinical Investigation |
| Vaccaro K, Allen J, Whitfield TW, et al. (2023) Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Biorxiv : the Preprint Server For Biology |
| Anderson KL, Snyder KM, Ito D, et al. (2019) Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade. Melanoma Research |
| Kohrt HE, Colevas AD, Houot R, et al. (2019) Targeting CD137 enhances the efficacy of cetuximab. The Journal of Clinical Investigation. 129: 2595 |
| Kohrt HE, Houot R, Weiskopf K, et al. (2019) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. The Journal of Clinical Investigation. 129: 2595 |
| Anderson KL, Snyder KM, Ito D, et al. (2019) Abstract A051: Melanoma displays an evolutionarily conserved resistance to upregulation of prophagocytic signals and to CD47 blockade Cancer Immunology Research. 7 |
| Barkal AA, Weiskopf K, Kao KS, et al. (2018) Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84 |
| Ring NG, Herndler-Brandstetter D, Weiskopf K, et al. (2017) Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proceedings of the National Academy of Sciences of the United States of America |